Jornay Pm

Attention Deficit Hyperactivity Disorder

Treatment

1 FDA approval

20 Active Studies for Jornay Pm

What is Jornay Pm

Dexmethylphenidate

The Generic name of this drug

Treatment Summary

Dexmethylphenidate is a stimulant drug used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. It was introduced in 2002 and works by increasing the activity of two neurotransmitters, norepinephrine and dopamine, in the brain. It is thought to be more effective than other forms of methylphenidate with fewer side effects.

Ritalin

is the brand name

image of different drug pills on a surface

Jornay Pm Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ritalin

Dexmethylphenidate

1955

400

Approved as Treatment by the FDA

Dexmethylphenidate, otherwise known as Ritalin, is approved by the FDA for 1 uses including Attention Deficit Hyperactivity Disorder .

Attention Deficit Hyperactivity Disorder

Helps manage Attention Deficit Hyperactivity Disorder (ADHD)

Effectiveness

How Jornay Pm Affects Patients

Dexmethylphenidate is a form of the drug methylphenidate. It is more powerful than the usual form, and works by blocking the reuptake of norepinephrine and dopamine in the brain.

How Jornay Pm works in the body

Methylphenidate works by blocking dopamine and norepinephrine transporters in certain areas of the brain, like the thalamus and striatum. This has been shown to affect blood flow and activity in parts of the brain, like the striatum, supplementary motor area, and posterior parietal cortex.

When to interrupt dosage

The proposed dosage of Jornay Pm is contingent upon the determined condition. The amount of dosage shifts, depending on the technique of administration (e.g. Tablet, film coated, extended release or Capsule, extended release) featured in the table beneath.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 15.0 mg, 25.0 mg, 35.0 mg, 2.5 mg, 10.0 mg/mL, 5.0 mg/mL, 18.0 mg, 36.0 mg, 27.0 mg, 54.0 mg, 72.0 mg, 85.0 mg, 55.0 mg, 45.0 mg, 70.0 mg, 80.0 mg, 60.0 mg, 100.0 mg, 50.0 mg, 10.4 mg, 6.0 mg/mL, 5.2 mg, 9.0 mg/mL, 30.0 mg/mL, 7.5 mg/mL, 7.8 mg, 1.0 mg/mL, 2.0 mg/mL

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Tablet, chewable - Oral, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release

Warnings

Jornay Pm has nine contraindications, and it is not to be taken along with any of the conditions outlined in the following table.

Jornay Pm Contraindications

Condition

Risk Level

Notes

Gilles de la Tourette syndrome

Do Not Combine

Tension-Type Headache

Do Not Combine

Agitation

Do Not Combine

Pulse Frequency

Do Not Combine

Tourette Syndrome

Do Not Combine

Tics

Do Not Combine

Generalized Anxiety Disorder

Do Not Combine

Open-angle glaucoma

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Dexmethylphenidate may interact with Pulse Frequency

There are 20 known major drug interactions with Jornay Pm.

Common Jornay Pm Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Desflurane

Major

Dexmethylphenidate may increase the hypertensive activities of Desflurane.

Diethyl ether

Major

Dexmethylphenidate may increase the hypertensive activities of Diethyl ether.

Enflurane

Major

Dexmethylphenidate may increase the hypertensive activities of Enflurane.

Ethanol

Major

Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Jornay Pm Toxicity & Overdose Risk

There is no difference in how men and women respond to dexmethylphenidate. Not much is known about how race, age, kidney and liver health, pregnancy, or breastfeeding affect the drug's effectiveness. Patients with kidney problems do not need a lower dose. Animal studies show that taking dexmethylphenidate during pregnancy or breastfeeding can delay fetal bone growth and reduce weight gain in male offspring. It is important to consider the benefits and risks of the drug before taking it. Dexmethylphenidate has not been linked to cancer, but mice exposed to extremely high doses developed liver tumors. There is also some weak evidence that it might be able to

image of a doctor in a lab doing drug, clinical research

Jornay Pm Novel Uses: Which Conditions Have a Clinical Trial Featuring Jornay Pm?

77 ongoing clinical trials are investigating the potential of Jornay Pm in providing relief for Attention Deficit Hyperactivity Disorder.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

61 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Jornay Pm Reviews: What are patients saying about Jornay Pm?

5

Patient Review

8/24/2022

Jornay Pm for Attention Deficit Disorder with Hyperactivity

Jornay has been an amazing medication for our daughter with ADHD. She's able to focus and be her best self all day long, without any negative side effects or impacting her sleep. We're looking forward to see how well she does in school this year!

5

Patient Review

8/31/2022

Jornay Pm for Attention Deficit Disorder with Hyperactivity

Jornay completely changed our lives by giving us our son back. If you have kids who struggle with medication, I urge you to try this out. You take it at night and they wake up feeling better, and the effects last all day!

5

Patient Review

9/14/2022

Jornay Pm for Attention Deficit Disorder with Hyperactivity

I've been taking medication for ADHD since 1991 and this is by far the best one I've tried. There are few to no side effects, just some mild appetite issues the first week or two. But other than that, it's very smooth and lasts a long time. I take the 80mg anywhere between 7-10pm and wake up as scheduled and have no problems falling asleep.

5

Patient Review

3/25/2022

Jornay Pm for Attention Deficit Disorder with Hyperactivity

I felt like this treatment helped me more than other similar treatments I've tried.

4.7

Patient Review

11/13/2021

Jornay Pm for Attention Deficit Disorder with Hyperactivity

My son, who is almost 11, has been taking this medication for a few months now. We switched from Adderall to Vyvanse, and it's been much better. Mornings were really tough before, but now he gets up on his own most of the time. He listens better and is doing great in school.

4.7

Patient Review

10/19/2022

Jornay Pm for Attention Deficit Disorder with Hyperactivity

So this has been really helpful for both myself and my daughter. We wake up feeling more rested and alert, which is such an improvement from before. And we don't even need the extra afternoon dose of Ritalin anymore! Our doctor said it's because the medication is absorbed in your large intestines, making it last longer?? I'm not sure how that works exactly, but all I know is that this has been a total win for us!

2.7

Patient Review

3/2/2020

Jornay Pm for Attention Deficit Disorder with Hyperactivity

My son took this for one month and it was an absolutely harrowing experience. Within a month, he went from getting A's in school to D's, and ended up having to be hospitalized after falling asleep in class and becoming catatonic. This was by far the worst reaction to any medication he's ever had.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about jornay pm

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Jornay PM cause anxiety?

"The side effects of the medication may include mood changes, anxiety, feeling nervous or irritable, trouble sleeping; fast heart rate, pounding heartbeats or fluttering in your chest; loss of appetite, weight loss; dry mouth, nausea, vomiting, stomach pain, indigestion."

Answered by AI

How many hours does Jornay pm last?

"Jornay PM should be taken in the evening and it uses delayed-release and extended-release technology to keep it from working for about 12 hours after it is taken. It is proven to control ADHD symptoms from the time of waking up and it lasts throughout the day."

Answered by AI

Is Jornay pm the same as Ritalin?

"Jornay PM has the same active ingredient as Ritalin and Daytrana. The FDA considers Jornay PM to be a federally controlled substance because it can be abused or lead to dependence."

Answered by AI

What does Jornay PM do?

"JORNAY PM is a prescription medicine used to treat ADHD that works by stimulating the central nervous system. It is approved for use in people aged 6 and above."

Answered by AI

Clinical Trials for Jornay Pm

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Jornay Pm clinical trials?

We made a collection of clinical trials featuring Jornay Pm, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Jornay Pm clinical trials?

We made a collection of clinical trials featuring Jornay Pm, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Jornay Pm clinical trials?

We made a collection of clinical trials featuring Jornay Pm, we think they might fit your search criteria.
Go to Trials